Abstract:Background: In the USA, the prolonged effective survival of cancer population has brought significant attention to the rising risk of cardiometabolic morbidity and mortality in this population. This heightened risk underscores the urgent need for research into effective pharmacological interventions for cancer survivors. Notably, metformin, a well-known metabolic regulator with pleiotropic effects, has shown protective effects against cardiometabolic disorders in diabetic individuals. Despite these promising indications, evidence supporting its efficacy in improving cardiometabolic outcomes in cancer survivors remains scarce. Methods: A prospective cohort was established using a nationally representative sample of cancer survivors enrolled in the US National Health and Nutrition Examination Survey (NHANES), spanning 2003 to 2018. Outcomes were derived from patient interviews, physical examinations, and public-access linked mortality archives up to 2019. The Oxidative Balance Score was utilized to assess participants' levels of oxidative stress. To evaluate the correlations between metformin use and the risk of cardiometabolic diseases and related mortality, survival analysis of cardiometabolic mortality was performed by Cox proportional hazards model, and cross-sectional analysis of cardiometabolic diseases outcomes was performed using logistic regression models. Interaction analyses were conducted to explore the specific pharmacological mechanism of metformin. Results: Among 3995 cancer survivors (weighted population, 21,671,061, weighted mean [SE] age, 62.62 [0.33] years; 2119 [53.04%] females; 2727 [68.26%] Non-Hispanic White individuals), 448 reported metformin usage. During the follow-up period of up to 17 years (median, 6.42 years), there were 1233 recorded deaths, including 481 deaths from cardiometabolic causes. Multivariable models indicated that metformin use was associated with a lower risk of all-cause (hazard ratio [HR], 0.62; 95% confidence interval [CI], 0.47-0.81) and cardiometabolic (HR, 0.65; 95% CI, 0.44-0.97) mortality compared with metformin nonusers. Metformin use was also correlated with a lower risk of total cardiovascular disease (odds ratio [OR], 0.41; 95% CI, 0.28-0.59), stroke (OR, 0.44; 95% CI, 0.26-0.74), hypertension (OR, 0.27; 95% CI, 0.14-0.52), and coronary heart disease (OR, 0.41; 95% CI, 0.21-0.78). The observed inverse associations were consistent across subgroup analyses in four specific cancer populations identified as cardiometabolic high-risk groups. Interaction analyses suggested that metformin use as compared to non-use may counter-balance oxidative stress. Conclusions: In this cohort study involving a nationally representative population of US cancer survivors, metformin use was significantly correlated with a lower risk of cardiometabolic diseases, all-cause mortality, and cardiometabolic mortality.

Metformin and other anti‐diabetic medication use and breast cancer incidence in the Nurses' Health Studies

Association of metformin use and cancer incidence: a systematic review and meta-analysis

Association Between Metformin Use and Coronary Artery Calcification in Type 2 Diabetic Patients

Metformin Is Associated With Slightly Reduced Risk Of Colorectal Cancer And Moderate Survival Benefits In Diabetes Mellitus: A Meta-Analysis

Metformin and Breast Cancer: Current Findings and Future Perspectives from Preclinical and Clinical Studies

Metformin Use May Increase Risk of Pancreatic Cancer in Diabetic Women: An Analysis of the Korean National Health Insurance Service-National Health Screening Cohort Database

Suppressive Effects of Metformin on Colorectal Adenoma Incidence and Malignant Progression

Metformin intervention in obese non-diabetic patients with breast cancer: phase II randomized, double-blind, placebo-controlled trial

Metformin Use on Incidence and Oncologic Outcomes of Bladder Cancer Patients With T2DM: An Updated Meta-Analysis

The association between metformin therapy and risk of gynecological cancer in patients: Two meta-analyses

The Effect of Metformin on the Clinicopathological Features of Breast Cancer with Type 2 Diabetes.

Diabetes Medication Use in Association with Survival among Patients of Breast, Colorectal, Lung, or Gastric Cancer

Metformin is Associated with Reduced Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis

Metformin Treatment for the Prevention and/or Treatment of Breast/Mammary Tumorigenesis

Association of metformin use with ovarian cancer incidence and prognosis: a systematic review and meta-analysis

Does metformin reduce the risk of cancer in obesity and diabetes? A systematic review and meta‐analysis

Metformin and cancer-specific survival among breast, colorectal, or endometrial cancer patients: A nationwide data linkage study

Metformin May Block the Way Breast Cancer Metastasis: A Meta-analysis and Mechanism Review

Metformin use correlated with lower risk of cardiometabolic diseases and related mortality among US cancer survivors: evidence from a nationally representative cohort study

Association Between Metformin Use and the Risk, Prognosis of Gynecologic Cancer

Metformin and lung cancer risk of patients with type 2 diabetes mellitus: A meta‑analysis